Aurora Cannabis Inc (ACB) reports a 29% increase in net revenue, driven by a 93% surge in international medical cannabis ...

Aurora Cannabis sees 29% YoY growth and solid cash flow, unaffected by U.S. market fears. Read why ACB stock remains a solid ...

Aurora Cannabis Inc (TSX:ACB) is set to release its Q2 2025 earnings on Nov 6, 2024. The consensus estimate for Q2 2025 ...

Q2 2025 Earnings Conference Call November 6, 2024 8:00 AM ETCompany ParticipantsKevin Niland - Director, Strategic ...

Aurora Cannabis (US) ( (ACB) ) has released its Q2 earnings. Here is a breakdown of the information Aurora Cannabis (US) presented to its ...

Q2 2025 Earnings Call Transcript November 6, 2024 Operator: Greetings and welcome to the Aurora Cannabis Inc. Second Quarter 2025 Results Conference Call. all participants will be in a listen-only ...

Aurora Cannabis reported quarterly revenue of CA$81.1 million, up from CA$63.1 million in the same period last year. Strong results are attributed to Aurora’s ability to capitalize on opportunities in ...

Aurora Cannabis' profit rose in its fiscal second quarter thanks to a strong performance from its medical cannabis unit. For the three months ended Sept. 30, the Canadian medical cannabis company on ...

Aurora Cannabis (TSE:ACB) has released an update. Aurora Cannabis reported impressive fiscal 2025 second-quarter results, achieving a record ...

Aurora's international medical cannabis business bolstered its results, with European sales doubling quarter-over-quarter.

CNW/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), a leading Canada-based global medical ...

Inc. (TSX: ACB) reported strong results in its fiscal Q2 2025 earnings, posting a 29% year-over-year increase in total revenue, reaching $81.1 million compared to $63.1 million in ...